MacroGenics Inc (NASDAQ:MGNX)
| 3.02 Delayed Data As of 3:59pm ET |  +0.01 / +0.33%Today’s Change | 2.13 Today|||52-Week Range 29.16 | -81.18% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $204.9M |
Company Description
MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Contact Information
MacroGenics, Inc. 9704 Medical Center Drive Rockville Maryland 20850-3368 |
Employees
Shareholders
| Other institutional | 53.40% |
| Mutual fund holders | 45.46% |
| Individual stakeholders | 26.16% |
Top Executives
| Scott E. Koenig | President, Chief Executive Officer & Director |
| Eric Risser | Chief Operating Officer |
| James Karrels | Chief Financial Officer, Secretary & Senior VP |
| Ezio Bonvini | Chief Scientific Officer & Senior VP-Research |
| Stephen L. Eck | Chief Medical Officer & SVP-Clinical Development |
